Clearside Biomedical (CLSD) to Release Quarterly Earnings on Thursday

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Tuesday, March 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The firm had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $3.40 million. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Stock Performance

CLSD opened at $1.28 on Wednesday. The business’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.25. The company has a market cap of $95.64 million, a price-to-earnings ratio of -2.42 and a beta of 2.35. Clearside Biomedical has a one year low of $0.65 and a one year high of $2.12.

Insider Activity

In related news, insider Ngai Hang Victor Chong acquired 30,000 shares of Clearside Biomedical stock in a transaction dated Wednesday, March 20th. The shares were acquired at an average cost of $1.60 per share, for a total transaction of $48,000.00. Following the completion of the transaction, the insider now directly owns 30,000 shares of the company’s stock, valued at $48,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on CLSD. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research report on Thursday, April 11th. StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday, March 14th. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Clearside Biomedical in a research report on Wednesday, March 13th. Finally, Wedbush restated an “outperform” rating and issued a $4.00 price objective (down from $5.00) on shares of Clearside Biomedical in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Clearside Biomedical currently has an average rating of “Moderate Buy” and a consensus price target of $4.75.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.